Connect your AI

Kura Oncology KURA Change in Other Assets

Change in Other Assets at other companies

AmgenAMGN

-$8M-104%

ExelixisEXEL

-$58.65M-189%

Syndax PharmaceuticalsSNDX

-$7.84M-30.8%

Corvus PharmaceuticalsCRVS

-$88K-7.3%

Nuvation BioNUVB

-$3.78M-2,509%

Arcus BiosciencesRCUS

$3M—

Other financials

Income statement

Revenue$18.3M+29.5%

Gross profit$18.0M—

Operating income-$78.8M-21.8%

Net income-$73.3M-27.7%

EPS (diluted)-$0.83-25.8%

Balance sheet

Cash & equivalents$39.1M-23.8%

Total debt$24.3M+25.4%

Total equity$107.9M-70.4%

Total assets$652.6M-12.3%

Cash flow

Operating cash flow-$85.9M-19.4%

CapEx$128.0K-56.2%

Free cash flow-$86.0M-19.1%

Valuation

Market cap$919.7M+81.6%

Enterprise value$904.89M+90.7%

P/S12.8×+3.5×

Profitability

Operating margin-443.5%+103pp

Net margin-411.2%+125pp

FCF margin130.6%+74.1pp

Returns & leverage

Return on equity-124.7%-252pp

Debt / equity0.2×+0.2×

Current ratio6.1×-1.9×

Where this comes from

Reported directly by Kura Oncology in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kura Oncology's change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Kura Oncology's change in other assets?: Kura Oncology (KURA) reported change in other assets of $562K in Q1 2026.
How has Kura Oncology's change in other assets changed year-over-year?: Kura Oncology's change in other assets decreased by 45.9% year-over-year, from $1.04M to $562K.
What does change in other assets mean?: Change in miscellaneous assets affecting operating cash flow.